Deferoxamine

Generic Name: Deferoxamine

Brand Names: Desferal

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₄₈N_₆O_₈

CAS Number: 70-51-9

Unique Ingredient Identifier: J06Y7MXW4D

Background: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Indication: Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.

Associated Conditions: Aluminum overload, Chronic Iron Overload, Chronic aluminum overload, Iron Overload

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Phase 4

Terminated

Conditions: Iron Overload
Other Anemias
Sickle Cell Disease

Interventions: Drug: Deferiprone
Drug: Deferoxamine

First Posted Date: 2014-01-22

Last Posted Date: 2021-08-10

Lead Sponsor: ApoPharma

Target Recruit Count: 230

Registration Number: NCT02041299

Locations: 🇺🇸
Children's Hospital, New Orleans, Louisiana, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇪🇬
Ains Shams University, Cairo, Egypt

and more 30 locations

High-Dose Deferoxamine in Intracerebral Hemorrhage

Phase 2

Terminated

Conditions: Intracerebral Hemorrhage

Interventions: Drug: Normal saline
Drug: Deferoxamine

First Posted Date: 2012-08-13

Last Posted Date: 2019-06-12

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 42

Registration Number: NCT01662895

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 26 locations

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload

Not Applicable

Completed

Conditions: Thalassemia
Iron Overload
Transfusion Related Complications

Interventions: Drug: osveral
Drug: Desferal

First Posted Date: 2011-06-09

Last Posted Date: 2011-06-14

Lead Sponsor: Hormozgan University of Medical Sciences

Target Recruit Count: 138

Registration Number: NCT01369719

Locations: 🇮🇷
Hormozgan University of Medical Sciences (HUMS), Bandar abbas, Hormozgan, Iran, Islamic Republic of

Modulation of Cerebral Blood Flow Using Iron Chelators

Early Phase 1

Completed

Conditions: Stroke
Problem of Aging

Interventions: Drug: desferrioxamine

First Posted Date: 2011-06-03

Last Posted Date: 2015-01-28

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 97

Registration Number: NCT01365104

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major

Phase 4

Completed

Conditions: Iron Overload
Cardiomyopathy

Interventions: Drug: Deferoxamine and Deferiprone
Drug: Deferoxamine

First Posted Date: 2008-12-02

Last Posted Date: 2008-12-02

Lead Sponsor: Ospedale Microcitemico

Registration Number: NCT00800761

Locations: 🇮🇹
Adult Talassemic Center, Ospedale Microcitemico, Cagliari, Sardinia, Italy

Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion

Phase 2

Completed

Conditions: Ischemic Stroke, Acute

Interventions: Drug: Deferoxamine

First Posted Date: 2008-10-22

Last Posted Date: 2022-08-08

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 62

Registration Number: NCT00777140

Locations: 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, Galicia, Spain
🇪🇸
Hospital Universitari Josep Trueta, Girona, Spain

and more 1 locations

Pilot Study for Patients With Poor Response to Deferasirox

Phase 4

Completed

Conditions: Transfusion-dependent Hemachromatosis
Sickle Cell Disease
Thalassemia Major

Interventions: Drug: Deferoxamine
Drug: Deferasirox
Radiation: HIDA

First Posted Date: 2008-09-09

Last Posted Date: 2024-02-12

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 15

Registration Number: NCT00749515

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Phase 1

Conditions: Thalassemia

Interventions: Drug: Deferoxamine
Drug: Deferasirox

First Posted Date: 2008-08-20

Last Posted Date: 2010-11-05

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 6

Registration Number: NCT00738413

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: deferoxamine

First Posted Date: 2008-04-15

Last Posted Date: 2013-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00658411

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Phase 2

Completed

Conditions: Transfusional Iron Overload
Transfusional Hemosiderosis

Interventions: Drug: Deferasirox
Drug: Deferoxamine

First Posted Date: 2008-01-25

Last Posted Date: 2014-08-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 197

Registration Number: NCT00600938

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy